Screening/Orientation

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Evaluation of samples with suspicion of acute leukemia. An initial screening step based on a limited number of antibodies orientates efficiently towards the most appropriate characterization panel (BCP-ALL, T-ALL & AML/SMD) (1).

  • The ALOT tube includes all the necessary markers to identify the different blast lines as well as MPAL (mixed phenotype acute leukemia): CD3, cyCD3, CD19, cyCD79a, cyMPO and CD7 which is positive in virtually all cases of T-ALL (1).
  • Suitable for evaluation of bone marrow and peripheral blood samples.
  • EuroFlow™ Databases for Automated Gating and Identification and Compass Classification tools included in Infinicyt™ for analysis automation and expert-guided interpretation (3).

Monitoring

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Characterization panels comprise the use of core markers to consistently identify the population of study in all tubes and other markers for characterization and classification of the cells in a specific  isease entity.

  • The use of premixed combinations reduces operational mistakes, pipetting time and inventory management requirements. Just add the required single antibodies to complete the panel.

Screening/Orientation

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Follow-up and sensitive quantification of MRD in BCP-ALL patients. MRD evaluation is one of the most significant prognostic factors in ALL for predicting disease recurrence (4-5).
  • Consistent panel of antibodies and fluorochromes:
    • Backbone markers for the evaluation of the B-cell maturation pathway. Evaluate the potential of the flow assay to detect normal BM cells that are regenerating after chemotherapy to reduce likelihood that those cells are misinterpreted as abnormal cells.
    • CD66c, CD123, CD73 and CD304 markers to define frequent abnormalities in BCP-ALL.
  • Suitable for evaluation of bone marrow, which is the most appropriate sample for BCP-ALL-MRD evaluation.
  • Pre-determined MRD thresholds for accurate reporting based on LOD and LLOQ and number of acquired events. Lower Limit of Detection and Limit of Quantitation should be reported after analysis in order to provide an objective result following current reporting guidelines.
  • High sensitivity close to 10-6, comparable to current PCR MRD evaluation sensitivity.
  • Applicable in virtually all BCP-ALL samples since no specific primers or probes are required.
  • Evaluate efficacy of treatment and individualized therapy monitoring by evaluation of the tumor load.